50
Participants
Start Date
December 11, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
December 30, 2025
dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen
Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)
Single arm
Baylor College of Medicine Children's Foundation, Kampala
Joint Research Centre, Kampala
University of Zimbabwe Clinical Research Centre, Harare
Collaborators (1)
Radboud University Medical Center
OTHER
Baylor College of Medicine
OTHER
Clinton Health Access Initiative Inc.
OTHER
University of Zimbabwe
OTHER
Chiang Mai University
OTHER
Joint Clinical Research Center
OTHER
PENTA Foundation
NETWORK